New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

doi:10.1186/1756-8722-2-22

Journal of Hematology & Oncology

Volume 2

Viewing options:

Abstract
Full text
PDF (370KB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on PubMed Central
Other articles by authors
on Google Scholar

Cang S
Ma Y
Liu D

on PubMed

Cang S
Ma Y
Liu D
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Review

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

Shundong Cang¹^,2 , Yuehua Ma¹^,2 and Delong Liu¹

¹Division of Hematology/Oncology, New York Medical College, Valhalla, NY 10595, USA

²Henan Province People's Hospital, Zhengzhou, PR China

author email corresponding author email

Journal of Hematology & Oncology 2009, 2:22doi:10.1186/1756-8722-2-22


Published:	1 June 2009

Abstract

DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.